17.45 USD
▼-1.63-8.54%
盘后 17.11 -1.95%
2026-10-23
市值
$259.22M
市盈率
—
EPS
-0.30
股息率
—
52 周区间
12.95 – 38.41
成交量
64.47K
Beta
—
目标价
—
52W 低 12.9552W 高 38.41
价格走势
公司简介
Vogenx, Inc. operates as a clinical-stage drug development company that develops therapeutics for metabolic including post-bariatric hypoglycemia, or PBH, and gastroparesis. Its products include drugs, such as Mizagliflozin and VGX-2857. It also offers VGX-001, a human monoclonal antibody for the treatment of type 1 diabetes (T1D). It caters to healthcare providers, physicians and third-party payors in the United States. The company was incorporated in 2021 and is based in Raleigh, North Carolina.